The DOI matches its Crossref record; 165 of the 166 references it cites were found in a registry or an index.
Tools for translation: non-viral materials for therapeutic mRNA delivery
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“To maximize translation, the mRNA sequence typically incorporates modified nucleosides, such as pseudouridine, N1-methylpseudouridine or other nucleoside analogues23.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [23]
In the citing paper
“mRNA has shown therapeutic potential in a range of applications, including viral vaccines, protein replacement therapies, cancer immunotherapies, cellular reprogramming and genome editing2,4,7–17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [7]
In the citing paper
“These lipids can improve nanoparticle properties, such as particle stability, delivery efficacy, tolerability and biodistribution7,14,17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [7]
In the citing paper
“Trapped in endosomes, in which the pH is lower than in the extracellular environment, ionizable lipids are protonated and, therefore, become positively charged, which may promote membrane destabilization and facilitate endosomal escape of the nanoparticles7,11,14”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [7]
In the citing paper
“To function in vivo, lipid nanoparticle–mRNA formulations need to overcome multiple extracellular and intracellular barriers7,11 (Fig. 3a).”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [7]
In the citing paper
“In addition to cationic or ionizable lipids, lipid nanoparticle–mRNA formulations typically contain other lipid components, such as phospholipids (for example, phosphatidylcholine and phosphatidylethanolamine), cholesterol or polyethylene glycol (PEG)-functionalized lipids (PEG-lipids)7,14,17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [7]
In the citing paper
“The pH-sensitivity of ionizable lipids is beneficial for mRNA delivery in vivo, because neutral lipids have less interactions with the anionic membranes of blood cells and, thus, improve the biocompatibility of lipid nanoparticles7,11,14.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [7]
In the citing paper
“mRNA normally contains five structural elements, that is, a 5′ cap, a 3′ poly(A) tail, a protein-coding sequence and 5′ and 3′ untranslated regions (UTRs)2,4,7,13.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [7]
In the citing paper
“These elements can be engineered to improve the stability and translational efficiency of mRNA2,4,7,13.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [7]
In the citing paper
“Chemical modifications of specific IVT mRNA nucleotides, such as pseudouridine (ψ) and N1-methylpseudouridine (m1ψ), can reduce innate immune sensing of exogenous mRNA translation2,4,7,182.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [7]
In the citing paper
“Chromatographic purification can remove double-stranded RNA, an analogue of viral genome, in IVT mRNA preparations, diminishing immune activation and increasing translational efficiency2,4,7,183.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [7]
In the citing paper
“To address these concerns, the engineering of mRNA molecules (Box 1) and the design of lipid nanoparticles have been optimized2,4,7–17, which has contributed to the rapid development and clinical assessment15,17 of the two COVID-19 mRNA vaccines, mRNA-1273 (NCT04470427)19,20 and BNT162b2 (NCT04368728)21.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [7]
In the citing paper
“Polymers, such as polyethyleneimine, protamine and polyaspartamide derivatives, are already widely used for mRNA delivery7–17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [7]
In the citing paper
“mRNA functions as the bridge between DNA and proteins in eukaryotic cells.[8, 12, 119]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [8]
In the citing paper
“Polyethylenimine (PEI) is one of the most developed cationic polymers [39], but its toxicity has limited the therapeutic applications.[8, 124]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [8]
In the citing paper
“Compared with protein drugs, mRNA can supplement both cytoplasmic and large transmembranic proteins.[8, 119, 120]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [8]
In the citing paper
“Recently, many biomaterials have been developed for mRNA delivery, including lipids and lipid derived materials, polymers, and many others. [8, 39, 120, 124]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [8]
In the citing paper
“Relative to plasmid DNA (pDNA), mRNA possesses temporary bioactivity and functions outside the nucleus, leading to a more controllable protein expression and avoiding the potential insertion of the genome.[8, 119, 120]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [8]
In the citing paper
“For many GARDs, the liver is a preferred organ for mRNA-based PRTs because systemically administrated mRNA vehicles are predominantly trapped by the reticuloendothelial system (RES) in the liver.”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [8]
In the citing paper
“In addition, the interaction between apolipoprotein E (apoE) and biomaterials such as lipid and lipid derived materials facilitates the accumulation in the liver.[8, 18, 34, 39, 59, 120, 121, 124, 164, 165]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [8]
In the citing paper
“Meanwhile, ionizable lipid and lipid derived materials, which acquire positive charges at low pH and become neutral at physiological pH, have been developed for decreasing the toxicity and immunogenicity while retaining the delivery efficiency.[8]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [8]
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Boussif, O., Lezoualc’h, F., Zanta, M. A., Djavaheri‐Mergny, M., Scherman, D., DEMENEIX, B. A., & Behr, J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.16.7297 · Cited by 6,256
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System
Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M., Makarova, K. S., Essletzbichler, P., Volz, S. E., Joung, J., van der Oost, J., Regev, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.038 · Cited by 4,761
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Research works printed but not linked: 1
- Moderna Therapeutics. Moderna Provides Pipeline and Full-Year Corporate Update. Moderna [online], https://www.modernatx.com/newsroom/press-releases/moderna-provides-pipeline-and-full-year-corporate-update (2017).
Cited by
Sorted by citations
Items 201–300 of 799
Ragelle, H., Rahimian, S., Guzzi, E. A., Westenskow, P. D., Tibbitt, M. W., Schwach, G., & Langer, R. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113990 · Cited by 76
Advances in Nanoparticles for Effective Delivery of RNA Therapeutics
Byun, M. J., Lim, J., Kim, S.-N., Park, D.-H., Kim, T. P., Park, W., & Park, C. G. (2022) · BioChip Journal · doi:10.1007/s13206-022-00052-5 · Cited by 78
“Applications in cancer immunotherapy, gene editing, and cell reprograming require protein expression for only a desired duration as well as high carrier stability, moderate binding force, efficient cellular uptake, and endosomal escape [93, 94].”
BackgroundThe mRNA Vaccine Revolution: COVID-19 Has Launched the Future of Vaccinology
Ye, Z., Harmon, J., Ni, W., Li, Y., Wich, D., & Xu, Q. (2023) · ACS Nano · doi:10.1021/acsnano.2c12584 · Cited by 72
mRNA – A game changer in regenerative medicine, cell-based therapy and reprogramming strategies
Chabanovska, O., Galow, A.-M., David, R., & Lemcke, H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114002 · Cited by 81
“A mature eukaryotic mRNA is composed of a nucleotide sequence with four distinct regions: cap structures at the 5́end, polyadenylated site at the 3́end and a protein-coding sequence flanked by untranslated regions (UTRs) at both 5́and 3́end [48].”
BackgroundLipid nanoparticle-mediated mRNA delivery in lung fibrosis
Massaro, M., Wu, S., Baudo, G., Liu, H., Collum, S. D., Lee, H., Stigliano, C., Segura-Ibarra, V., Karmouty‐Quintana, H., & Blanco, E. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106370 · Cited by 77
“Cholesterol was incorporated to further enhance LNP stability through improved membrane rigidity and integrity (Meng et al., 2021; Hajj and Whitehead, 2017).”
BackgroundLipid nanoparticles for mRNA delivery in brain via systemic administration
Cao, D., Hou, X., Wang, C., Wang, S., Liu, Z., Tian, M., Guo, K., Li, H., Kang, D. D., Zhong, Y., et al. (2025) · Science Advances · doi:10.1126/sciadv.adw0730 · Cited by 79
Engineering Antiviral Vaccines
Zhou, X., Jiang, X., Qu, M., Aninwene, G. E., Jucaud, V., Moon, J. J., Gu, Z., Sun, W., & Khademhosseini, A. (2020) · ACS Nano · doi:10.1021/acsnano.0c06109 · Cited by 72
Nanotechnology‐Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVID‐19 Vaccines
Rinoldi, C., Zargarian, S. S., Nakielski, P., Li, X., Liguori, A., Petronella, F., Presutti, D., Wang, Q., Costantini, M., Sio, L. D., et al. (2021) · Small Methods · doi:10.1002/smtd.202100402 · Cited by 78
Wang, Y., Tang, J., Yang, Y., Song, H., Fu, J., Gu, Z., & Yu, C. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201914264 · Cited by 71
Delivery of therapeutic oligonucleotides in nanoscale
Wu, L., Zhou, W., Lin, L., Chen, A., Feng, J. C., Qu, X., Zhang, H., & Yue, J. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.05.038 · Cited by 72
Size and Charge Characterization of Lipid Nanoparticles for mRNA Vaccines
Malburet, C., Leclercq, L., Cotte, J., Thiebaud, J., Bazin, E., Garinot, M., & Cottet, H. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.1c04778 · Cited by 75
Young, R. E., Nelson, K. M., Hofbauer, S. I., Vijayakumar, T., Alameh, M., Weissman, D., Papachristou, C., Gleghorn, J. P., & Riley, R. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.11.014 · Cited by 77
“Thus, various approaches to engineering novel mRNA delivery vehicles have emerged to promote high transfection and low toxicity [10].”
BackgroundMucosal immunity and vaccination strategies: current insights and future perspectives
Zhang, Z., Hong, W., Zhang, Y., Li, X., Que, H., & Wei, X. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00301-7 · Cited by 81
Recent advances in mRNA vaccine delivery
Tan, L., & Sun, X. (2018) · Nano Research · doi:10.1007/s12274-018-2091-z · Cited by 71
“They typically consist of four components, including a cationic or ionizable lipid, cholesterol, a helper phospholipid, and a polyethylene glycol (PEG) lipid [65].”
BackgroundNanomedicine-based immunotherapy for central nervous system disorders
Hanif, S., Muhammad, P., Chesworth, R., Rehman, F. U., Qian, R., Zheng, M., & Shi, B. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0429-z · Cited by 69
Gilbert, J., Sebastiani, F., Arteta, M. Y., Terry, A. E., Fornell, A., Russell, R. A., Mahmoudi, N., & Nylander, T. (2024) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2023.12.165 · Cited by 66
Supramolecular interaction in the action of drug delivery systems
Geng, W.-C., Jiang, Z.-T., Chen, S., & Guo, D. (2024) · Chemical Science · doi:10.1039/d3sc04585d · Cited by 71
“84,85 In the triumphant P zer/BioNTech BNT162b2 and Moderna mRNA-1273 COVID-19 vaccines, lipid nanoparticles protecting mRNA through encapsulating the hydrophilic mRNA by non-covalent supramolecular interactions, such as hydrogen bonding and electrostatic interactions (Fig.”
BackgroundElkassih, S. A., Kós, P., Xiong, H., & Siegwart, D. J. (2018) · Biomaterials Science · doi:10.1039/c8bm01120f · Cited by 65
Hameed, S. A., Paul, S., Dellosa, G. K. Y., Jaraquemada, D., & Bello, M. B. (2022) · npj Vaccines · doi:10.1038/s41541-022-00485-x · Cited by 65
Advanced delivery systems for peptide antibiotics
Cesaro, A., Lin, S., Pardi, N., & de la Fuente‐Núñez, C. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114733 · Cited by 67
Serum Nuclease Susceptibility of mRNA Cargo in Condensed Polyplexes
Yen, A., Cheng, Y., Sylvestre, M., Gustafson, H. H., Puri, S., & Pun, S. H. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00134 · Cited by 69
Amniotic fluid stabilized lipid nanoparticles for in utero intra-amniotic mRNA delivery
Swingle, K. L., Billingsley, M. M., Bose, S. K., White, B., Palanki, R., Dave, A., Patel, S. K., Gong, N., Hamilton, A. G., Alameh, M.-G., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.10.031 · Cited by 64
“Additional challenges of viral vectors such as immunogenicity and limitations regarding repeat dosing can be addressed with non-viral nucleic acid delivery [20,22].”
BackgroundInfluentialExploiting the placenta for nanoparticle-mediated drug delivery during pregnancy
Figueroa‐Espada, C. G., Hofbauer, S. I., Mitchell, M. J., & Riley, R. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.09.006 · Cited by 65
Non-viral transfection technologies for next-generation therapeutic T cell engineering
Raes, L., Smedt, S. C. D., Raemdonck, K., & Braeckmans, K. (2021) · Biotechnology Advances · doi:10.1016/j.biotechadv.2021.107760 · Cited by 67
“Even though polymeric carriers are not as clinically advanced compared to LNPs, they hold potential as ex vivo delivery carrier for T cell engineering (Hajj and Whitehead, 2017).”
BackgroundOsterloh, A. (2022) · Vaccines · doi:10.3390/vaccines10050751 · Cited by 63
Jacobson, M. E., Wang-Bishop, L., Becker, K. W., & Wilson, J. T. (2018) · Biomaterials Science · doi:10.1039/c8bm01064a · Cited by 62
Zhang, C., Zhang, X., Zhao, W., Zeng, C., Li, W., Li, B., Luo, X., Li, J., Jiang, J., Deng, B., et al. (2019) · Nano Research · doi:10.1007/s12274-019-2308-9 · Cited by 61
Delivery technologies for in utero gene therapy
Palanki, R., Peranteau, W. H., & Mitchell, M. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.11.002 · Cited by 64
Therapeutic Approaches for Patients with Cystic Fibrosis Not Eligible for Current CFTR Modulators
Fajac, I., & Sermet‐Gaudelus, I. (2021) · Cells · doi:10.3390/cells10102793 · Cited by 61
Engineering Biomaterials with Micro/Nanotechnologies for Cell Reprogramming
Fang, J., Hsueh, Y., Soto, J., Sun, W., Wang, J., Gu, Z., Khademhosseini, A., & Li, S. (2020) · ACS Nano · doi:10.1021/acsnano.9b04837 · Cited by 61
Wang, F., Xiao, W., Elbahnasawy, M. A., Bao, X., Zheng, Q., Gong, L., Zhou, Y., Yang, S., Fang, A., Farag, M. M. S., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00980 · Cited by 59
Ongoing Clinical Trials of Nonviral siRNA Therapeutics
Narasipura, E. A., VanKeulen‐Miller, R., Ma, Y., & Fenton, O. S. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00205 · Cited by 66
Micro/nanosystems for controllable drug delivery to the brain
Tian, M., Ma, Z., & Yang, G. (2023) · The Innovation · doi:10.1016/j.xinn.2023.100548 · Cited by 64
“136 139 Liposomes have also emerged as vehicles for gene delivery, most notably in the clinical application of lipid NP-mRNA vaccines against COVID-19, marking a milestone in mRNA therapeutics.”
BackgroundYoshinaga, N., Uchida, S., Naito, M., Osada, K., Cabral, H., & Kataoka, K. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.01.023 · Cited by 59
A polyphenol-assisted IL-10 mRNA delivery system for ulcerative colitis
Chen, Z., Hao, W., Gao, C., Zhou, Y. Y., Zhang, C., Zhang, J., Wang, R., Wang, Y., & Wang, S. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.03.025 · Cited by 58
“Acta Pharmaceutica Sinica B 2022;12(8):3367e3382”
Li, C. Y., Liang, Z., Hu, Y., Zhang, H., Setiasabda, K. D., Li, J., Ma, S., Xia, X., & Kuang, Y. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.10.003 · Cited by 58
Targeting materials and strategies for RNA delivery
Lin, L., Su, K., Cheng, Q., & Liu, S. (2023) · Theranostics · doi:10.7150/thno.87316 · Cited by 61
From Endocytosis to Nonendocytosis: The Emerging Era of Gene Delivery
Zhou, J. J., Shao, Z., Liu, J., Duan, Q., Wang, X., Li, J., & Yang, H. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.9b01131 · Cited by 59
mRNA, a Revolution in Biomedicine
Baptista, B., Carapito, R., Laroui, N., Pichon, C., & de Sousa, F. P. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122090 · Cited by 61
“The degradation of mRNA can be determined by its structure, thus allowing improved, controllable and temporary pharmacokinetics [1,12,15].”
BackgroundMethodInfluentialNonviral Delivery Systems of mRNA Vaccines for Cancer Gene Therapy
Wang, Y., Zhang, R., Tang, L., & Li, Y. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030512 · Cited by 58
“Then, mRNA-loaded LNPs are injected into the body and subsequently enter targeted cells by interacting with negatively charged cell membrane components or specific proteins exposed on the cell membrane [82].”
BackgroundDevelopment and applications of mRNA treatment based on lipid nanoparticles
Wang, Z., Ma, W., Fu, X., Qi, Y., Zhao, Y., & Zhang, S. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108130 · Cited by 57
Deshmukh, R., Sethi, P., Singh, B., Shiekmydeen, J., Salave, S., Patel, R. J., Ali, N., Rashid, S., Elossaily, G. M., & Kumar, A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16081076 · Cited by 60
“Methods for delivering therapeutic mRNA and siRNA have been summarised in other in-depth reviews [190,191].”
BackgroundYoshinaga, N., Cho, E., Koji, K., Mochida, Y., Naito, M., Osada, K., Kataoka, K., Cabral, H., & Uchida, S. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201905203 · Cited by 57
Messenger RNA-Based Vaccines Against Infectious Diseases
Alameh, M.-G., Weissman, D., & Pardi, N. (2020) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2020_202 · Cited by 96
Nanotechnologies in Delivery of DNA and mRNA Vaccines to the Nasal and Pulmonary Mucosa
Tang, J., Cai, L., Xu, C., Sun, S., Liu, Y., Rosenecker, J., & Guan, S. (2022) · Nanomaterials · doi:10.3390/nano12020226 · Cited by 54
Nebulised delivery of RNA formulations to the lungs: From aerosol to cytosol
Neary, M. T., Mulder, L. M., Kowalski, P. S., MacLoughlin, R. J., Crean, A. M., & Ryan, K. B. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.012 · Cited by 63
Lipid-Based Vectors for Therapeutic mRNA-Based Anti-Cancer Vaccines
Guevara, M. L., Persano, S., & Persano, F. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190619150221 · Cited by 57
Yoshinaga, N., Uchida, S., Dirisala, A., Naito, M., Osada, K., Cabral, H., & Kataoka, K. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.12.033 · Cited by 58
Clinical progress of nanomedicine-based RNA therapies
Lim, S. A., Cox, A., Tung, M., & Chung, E. J. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.10.018 · Cited by 57
Branched hydrophobic tails in lipid nanoparticles enhance mRNA delivery for cancer immunotherapy
Yan, Y., Liu, X., Wang, L., Wu, C., Shuai, Q., Zhang, Y., & Liu, S. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122279 · Cited by 56
Lu, J., Atochina‐Vasserman, E. N., Maurya, D. S., Sahoo, D., Ona, N. A., Reagan, E. K., Ni, H., Weissman, D., & Percec, V. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c07337 · Cited by 55
Miyazaki, T., Uchida, S., Nagatoishi, S., Koji, K., Hong, T., Fukushima, S., Tsumoto, K., Ishihara, K., Kataoka, K., & Cabral, H. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202000538 · Cited by 56
Vaccination with Messenger RNA: A Promising Alternative to DNA Vaccination
Tombácz, I., Weissman, D., & Pardi, N. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0872-2_2 · Cited by 55
Recent advancements in lipid–mRNA nanoparticles as a treatment option for cancer immunotherapy
Karmacharya, P., Patil, B. R., & Kim, J. O. (2022) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-022-00569-9 · Cited by 54
Bibri, S. E. (2023) · Smart Cities · doi:10.3390/smartcities6030065 · Cited by 62
Sahoo, D., Atochina‐Vasserman, E. N., Maurya, D. S., Arshad, M., Chenna, S. S., Ona, N. A., Vasserman, J. A., Ni, H., Weissman, D., & Percec, V. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.3c13569 · Cited by 54
Zhu, Y., He, M., Lin, C., Ma, W., Ai, Y., Wang, J., & Liang, Q. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202502178 · Cited by 61
A scalable and robust cationic lipid/polymer hybrid nanoparticle platform for mRNA delivery
Meyer, R. A., Hussmann, G. P., Peterson, N. C., Santos, J. L., & Tuesca, A. D. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121314 · Cited by 57
Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery
Han, G., Noh, D., Lee, H., Lee, S., Kim, S., Yoon, H. Y., & Hyeon, L. S. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114973 · Cited by 53
“Although the development and applications of mRNA in cancer vaccines have some limitations, such as biological instability and poor pharmacokinetics of mRNA, and insufficient in vitro and in vivo delivery efficiency due to its negatively-charged and large-sized property [28, 29], researchers have developed various des…”
Transdermal delivery for gene therapy
Singh, P., Muhammad, I., Nelson, N. E., Tran, K. T. M., Vinikoor, T., Chorsi, M. T., D’Orio, E., & Nguyen, T. D. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01138-1 · Cited by 52
“Notably, polymeric- or lipid-based particles have gained popularity with the recently implemented mRNA SARS-COV-19 vaccines [13, 139, 140].”
BackgroundEmerging Concepts of Nanobiotechnology in mRNA Delivery
Wang, Y., & Yu, C. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202003545 · Cited by 54
Hybrid core-shell particles for mRNA systemic delivery
Andretto, V., Repellin, M., Pujol, M., Almouazen, E., Sidi‐Boumedine, J., Granjon, T., Zhang, H., Remaut, K., Jordheim, L. P., Briançon, S., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.042 · Cited by 57
High‐Precision Synthesis of RNA‐Loaded Lipid Nanoparticles for Biomedical Applications
Seo, H., Jeon, L., Kwon, J., & Lee, H. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202203033 · Cited by 54
An Overview of Nanoparticle-Based Delivery Platforms for mRNA Vaccines for Treating Cancer
Yang, L., Chen, X., Wang, K., Li, L., & Zhang, H. (2024) · Vaccines · doi:10.3390/vaccines12070727 · Cited by 55
“In another example, mRNA could be delivered by ionizable lipid nanoparticles (iLNPs) to placental trophoblasts, endothelial cells, and immune cells in clinical practice [35].”
BackgroundThe Potential of Cell-Penetrating Peptides for mRNA Delivery to Cancer Cells
Kim, Y., Kim, H., Kim, E. H., Jang, H., Jang, Y., Chi, S.-G., Yang, Y., & Kim, S. H. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061271 · Cited by 50
“In this regard, lipid- and polymer-based systems have been extensively studied, especially through the development of COVID-19 vaccines [16,17].”
BackgroundChen, W., Li, X., Cheng, H., & Xia, W. (2022) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2022.10.008 · Cited by 50
Hu, M., Feng, C., Yuan, Q., Liu, C., Ge, B., Sun, F., & Zhu, X. (2023) · Nature Communications · doi:10.1038/s41467-023-37020-y · Cited by 50
Nanomedicine for T‐Cell Mediated Immunotherapy
Li, F., Ouyang, J., Chen, Z., Zhou, Z., Essola, J. M., Ali, B., Wu, X., Zhu, M., Guo, W., & Liang, X. (2023) · Advanced Materials · doi:10.1002/adma.202301770 · Cited by 51
Advances in lipid nanoparticle mRNA therapeutics beyond COVID-19 vaccines
Wu, Y., Yu, S., & de Lázaro, I. (2024) · Nanoscale · doi:10.1039/d4nr00019f · Cited by 51
Scaffold-mediated delivery for non-viral mRNA vaccines
Chen, R., Zhang, H., Yan, J., & Bryers, J. D. (2018) · Gene Therapy · doi:10.1038/s41434-018-0040-9 · Cited by 50
Nanomedicines for the Delivery of Biologics
Wahlich, J. C., Desai, A. S., Greco, F., Hill, K. J., Jones, A. T., Mrsny, R. J., Pasut, G., Perrie, Y., Seib, F. P., Seymour, L. W., et al. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11050210 · Cited by 51
“However, mRNAs, in contrast, require advanced formulations and a delivery system [46].”
BackgroundKoji, K., Yoshinaga, N., Mochida, Y., Hong, T., Miyazaki, T., Kataoka, K., Osada, K., Cabral, H., & Uchida, S. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120332 · Cited by 51
Nanovesicle-Mediated Delivery Systems for CRISPR/Cas Genome Editing
Kim, D., Le, Q., Wu, Y., Park, J.-W., & Oh, Y. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121233 · Cited by 51
Blakney, A. K., Deletic, P., McKay, P. F., Bouton, C. R., Ashford, M., Shattock, R. J., & Sabirsh, A. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.11.033 · Cited by 48
Disulfide Bridging Strategies in Viral and Nonviral Platforms for Nucleic Acid Delivery
Dutta, K., Das, R., Medeiros, J., & Thayumanavan, S. (2021) · Biochemistry · doi:10.1021/acs.biochem.0c00860 · Cited by 49
Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders
Guo, Z.-H., Khattak, S., Rauf, M. A., Ansari, M. A., Alomary, M. N., Razak, S., Yang, C., Wu, D., & Ji, X. (2023) · Molecules · doi:10.3390/molecules28031283 · Cited by 49
Cellular Trafficking of Nanotechnology‐Mediated mRNA Delivery
Huang, P., Deng, H., Wang, C., Zhou, Y., & Chen, X. S. (2023) · Advanced Materials · doi:10.1002/adma.202307822 · Cited by 53
Ayad, C., Libeau, P., Lacroix, C., Ladavière, C., & Verrier, B. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030377 · Cited by 48
“Firstly, mRNA is not infectious (unlike whole virus delivery) and cannot integrate into the host’s genome or alter it (which may be a risk with DNA, which needs to reach the nucleus to be decoded) [5,6].”
BackgroundInfluentialBiomaterials-Mediated Engineering of the Immune System
Backlund, C. M., Jalili‐Firoozinezhad, S., Kim, B., & Irvine, D. J. (2023) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101721-040259 · Cited by 52
Dehghani‐Ghahnaviyeh, S., Smith, M., Xia, Y., Dousis, A. D., Grossfield, A. M., & Sur, S. (2023) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.3c01296 · Cited by 47
Forenzo, C., & Larsen, J. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00439 · Cited by 48
Dynamic mRNA polyplexes benefit from bioreducible cleavage sites for in vitro and in vivo transfer
Levačić, A. K., Berger, S., Müller, J., Wegner, A., Lächelt, U., Dohmen, C., Rudolph, C., & Wagner, E. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.09.016 · Cited by 47
Cystic Fibrosis: Overview of the Current Development Trends and Innovative Therapeutic Strategies
Almughem, F. A., Aldossary, A. M., Tawfik, E. A., Alomary, M. N., Alharbi, W. S., Alshahrani, M. Y., & Alshehri, A. A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12070616 · Cited by 53
mRNA Vaccines: Why Is the Biology of Retroposition Ignored?
Domazet‐Lošo, T. (2022) · Genes · doi:10.3390/genes13050719 · Cited by 47
The tumor therapeutic potential of long non-coding RNA delivery and targeting
Han, S., Chen, X., & Huang, L. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.12.005 · Cited by 46
Zeng, Y., Sentí, M. E., Labonia, M. C. I., Papadopoulou, P., Brans, M. A. D., Dokter, I., Fens, M. H. A. M., van Mil, A., Sluijter, J. P. G., Schiffelers, R. M., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c05341 · Cited by 48
Noncationic Material Design for Nucleic Acid Delivery
Jiang, Z., & Thayumanavan, S. (2020) · Advanced Therapeutics · doi:10.1002/adtp.201900206 · Cited by 46
Jung, O., Jung, H., Thủy, L. T. T., Choi, M., Kim, S., Jeon, H., Yang, J., Kim, S., Kim, T., Lee, E., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202303857 · Cited by 47
Recent developments of polymeric delivery systems in gene therapeutics
Li, Y., Tian, R., Xu, J., Zou, Y., Wang, T., & Liu, J. (2024) · Polymer Chemistry · doi:10.1039/d4py00124a · Cited by 48
Shi, R., Liu, X., Wang, Y., Pan, M., Wang, S., Shi, L., & Ni, B. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2342592 · Cited by 48
Chen, Z., Yang, Y., Qiu, X., Zhou, H., Wang, R., & Xiong, H. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c14500 · Cited by 46
Zhang, H., Rombouts, K., Raes, L., Xiong, R., Smedt, S. C. D., Braeckmans, K., & Remaut, K. (2020) · Advanced Biosystems · doi:10.1002/adbi.202000057 · Cited by 45
Advances in genome editing for genetic hearing loss
Ding, N., Lee, S., Lieber-Kotz, M., Yang, J., & Gao, X. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.001 · Cited by 43
“To address this problem, some lipoplexes and polyplexes, such as polyethyleneimine, protamine, TransIT and MegaFectin, have been adapted to the Cas9 mRNA delivery in recent years [21, 143].”
BackgroundHoecke, L. V., Verbeke, R., Vlieger, D. D., Dewitte, H., Roose, K., Nevel, S. V., Krysko, O., Bachert, C., Schepens, B., Lentacker, I., et al. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.04.015 · Cited by 46
Cancer Nanomedicines in an Evolving Oncology Landscape
Guo, P., Huang, J., & Moses, M. A. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.08.001 · Cited by 42
Efficient Delivery of mRNA Using Crosslinked Nucleic Acid Nanogel as a Carrier
Huang, X., Zheng, R., Ding, F., Yang, J., Xie, M., Liu, X., Li, J., Feng, J. C., Zhu, X., & Zhang, C. (2020) · ACS Materials Letters · doi:10.1021/acsmaterialslett.0c00375 · Cited by 44
Hepatocellular-Targeted mRNA Delivery Using Functionalized Selenium Nanoparticles In Vitro
Singh, D., & Singh, M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030298 · Cited by 45
Lipid Nanoparticle-Based Delivery SystemA Competing Place for mRNA Vaccines
Zhang, X., Li, Y., & Zhou, Z. (2024) · ACS Omega · doi:10.1021/acsomega.3c08353 · Cited by 43
Lipid‐Modified Aminoglycosides for mRNA Delivery to the Liver
Yu, X., Liu, S., Cheng, Q., Wei, T., Lee, S. M., Zhang, D., & Siegwart, D. J. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.201901487 · Cited by 46
Scope and challenges of nanoparticle-based mRNA delivery in cancer treatment
Karim, M. E., Haque, S. T., Al-Busaidi, H., Bakhtiar, A., Tha, K. K., Holl, M. M. B., & Chowdhury, E. H. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01418-x · Cited by 45
Metadata
- Authors
- Hajj, K. A., & Whitehead, K. A.
- Affiliations
- Carnegie Mellon University (US)
- Corresponding author
- Whitehead, Kathryn A.
- Venue
- Nature Reviews Materials
- Published
- 2017-09-12
- Volume
- 2
- Issue
- 10
- ISSN
- 2058-8437 (ISSN-L)
- OpenAlex
- W2754401101
- Cited by
- 799
- References
- 166
- Citations by year
- 2026: 61 · 2025: 122 · 2024: 110 · 2023: 126 · 2022: 124 · 2021: 101 · 2020: 82 · 2019: 40 · 2018: 32 · 2017: 1
- FWCI
- 3.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Nature Reviews Materials (publishedVersion)
- Funders
- Defense Advanced Research Projects Agency (D16AP00143)
- Advanced Research Projects Agency
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Keywords
- mRNA therapeutics, mRNA delivery, synthetic materials, lipid nanoparticles, mRNA vaccines, cancer immunotherapy, in vitro transcribed mRNA
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
